close
Medical products

Kenya and Novo Nordisk sign MoU to provide medical products to children with diabetes

The Government of Kenya and Novo Nordisk, a Danish multinational pharmaceutical company, have signed a memorandum of understanding for the supply of medical products to improve the treatment and self-management of type 1 diabetes in children.

Speaking at the ceremony, Cabinet Secretary for Health Mutahi Kagwe said the long-term aspiration of the program was not only to improve the lives of children enrolled in the project, but also to find ways to integrate the components of the program into the delivery of health care in the country.

He said the parties have entered into a partnership to use their respective skills and strengths to improve the well-being of people living with diabetes in Kenya through sustainable partnerships and collaborations, as well as to improve the diabetes care for children with type 1 diabetes in Kenya. the country.

“We welcome you and thank you for your support. Your partnership is important and we value it. We invite you to think about investing in the country in terms of manufacturing,” said the Health CS.

To reach more children with diabetes, Kenya needs to establish additional type 1 diabetes clinics and build the capacity of health workers, with Novo Nordisk committing two billion shillings to support the program for the next 3 years.

The two parties have agreed on how to improve and establish the infrastructure of diabetes clinics and the provision of medical and laboratory equipment, training and education of health professionals working on diabetes in type 1 in children and adolescents, the provision of human insulin and blood glucose monitoring equipment and supplies at no cost to children and adolescents. They also agreed to educate children and teens with type 1 diabetes and their families, create a registry for children and teens with type 1 diabetes, and share ideas and results for improvement. Continuation of the Changing Diabetes in Children Project between parties. .

In the agreement, the Government of Kenya will be obliged, among other things, to gradually integrate the Changing Diabetes in Children program into the national health system and to ensure that diabetes and specifically type 1 diabetes is included in the national non-communicable disease agenda. consistent with the Sustainable Development Goals.

Novo Nordisk, in turn, will have to provide the diagnostic, screening and monitoring equipment necessary for the organization and operation of diabetes clinics and the patient registry, provide free human insulin to cover diabetes treatment needs type 1 in children and adolescents up to 25 years old in the health structures supported by the CDiC project.

The company will also have to support the training of health professionals in the management of type 1 diabetes in children and adolescents, support awareness campaigns in collaboration with various stakeholders, support education on diabetes self-management for children, adolescents and their families, including development The CDiC project provides educational materials to patients and supports the improvement of infrastructure in some of the diabetes clinics, as determined by the ministry of Health.

The MoU was signed by Vinay Ransiwal, Managing Director and Vice President on behalf of Novo Nordisk and CS Mutahi Kagwe on behalf of the Government of Kenya and in the presence of Danish Ambassador to Kenya Ole Thonke.

The Changing Children’s Diabetes program was launched in Kenya in 2012 to ensure that children with type 1 diabetes have access to appropriate treatment and support. The partnership was between Novo Nordisk, the Government of Kenya, Roche Diabetes and the Kenya Diabetes Management and Information Center (DMI). It was created to identify solutions that can lead to an integrated approach to the diagnosis, treatment and control of diabetes in children with type 1 diabetes.

(With contributions from APO)

Joan J. Dean

The author Joan J. Dean